TITLE

FDA panel votes to pull Avastin in breast cancer, again

AUTHOR(S)
Ratner, Mark
PUB. DATE
August 2011
SOURCE
Nature Biotechnology;Aug2011, Vol. 29 Issue 8, p676
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article focuses on an announcement by a panel of advisors of the U.S. Food and Drug Administration (FDA) that the cancer drug Avastin from Genentech is inefficient when used with chemotherapy as an initial treatment for breast cancer.
ACCESSION #
63884120

 

Related Articles

  • Avastin Garners Support on Comment Board.  // BioWorld Today;8/1/2011, Vol. 22 Issue 147, p6 

    The article reports that the U.S. Food and Drug Administration's (FDA) proposal to withdraw its approval for Genentech Inc.'s Avastin as a breast cancer treatment has generated many comments from patients citing anecdotal information that contradicts the findings of the Oncologic Drugs Advisory...

  • Genentech Seeks Avastin Use for Glioblastoma.  // Bioworld Week;11/10/2008, Vol. 16 Issue 45, p3 

    The article reports on the move of Genentech Inc. to submit a supplemental biologics license application to the U.S. Food and Drug Administration (FDA) for Avastin as a therapy for people with previously treated glioblastoma, an aggressive form of brain cancer. It states that if the FDA accepted...

  • Genentech Objects to FDA Decision on Avastin.  // BioWorld Today;1/3/2011, Vol. 22 Issue 1, p5 

    The article reports that Genentech Inc. requested a hearing on the decision by the U.S. Food and Drug Administration (FDA) to reject the firm's Avastin as treatment for HER2-negative breast cancer in combination with paclitaxel because four follow-up studies did not prove prolonged overall...

  • FDA Splits with ODAC, OKs Avastin Use in Breast Cancer. Morrison, Trista // BioWorld Today;2/25/2008, Vol. 19 Issue 37, p1 

    The article reports on the split decision between the U.S. Food and Drug Administration (FDA) and Oncologic Drugs Advisory Committee (ODAC) over the new breast cancer drug, Avastin by Genentech Inc. It is inferred that the approval by FDA of the drug could translate to double revenue for the...

  • Genentech/Roche: Avastin adds fifth indication to label.  // PharmaWatch: Cancer;Jun2009, Vol. 8 Issue 6, p13 

    The article discusses the positive results of a trial in the U.S. for the drug Avastin from the merged company of Genentech Inc. and Roche Holding AG as this development becomes the fifth indication for approval of the drug. The Food and Drug Administration (FDA) gives the full approval for such...

  • FDA APPROVES AVASTIN FOR THE MOST COMMON KIDNEY CANCER.  // Biotech Business;Sep2009, Vol. 22 Issue 9, p7 

    The article reports on the approval by the U.S. Food and Drug Administration (FDA) of Genentech Inc.'s Avastin plus interferon-alfa for people with metastatic renal cell carcinoma. According to executive vice president Hal Barron, Avastin has been approved to treat different types of cancer....

  • REDUCING THE REGULATORY ROLE OF THE FDA: PROMOTING PATIENT AUTONOMY TO CHOOSE AVASTIN AND OTHER CANCER DRUGS. RAY, SARA J. // Connecticut Law Review;Nov2012, Vol. 45 Issue 1, p319 

    On November 18, 2011, the Food and Drug Administration (FDA) revoked accelerated approval of the breast cancer indication for Avastin, a cancer drug manufactured by Genentech. The FDA claims that Avastin, when used to treat metastatic breast cancer, does not provide a benefit that justifies the...

  • Drug Warnings: Ranibizumab and Bevacizumab. Elliott, William T. // Clinical Cardiology Alert;Mar2007 Pharmacology Watch, p2 

    The article focuses on the warnings issued by the U.S. Food and Drug Administration (FDA) regarding the use of anti-angiogenic drugs ranibizumab and bevacizumab, manufactured by Genentech. Ranibizumab has been found to be associated with increased risk of stroke in elderly patients, while...

  • Drug Warnings: Ranibizumab and Bevacizumab. Elliott, William T. // Clinical Oncology Alert;Mar2007 Pharmacology Watch, p2 

    The article focuses on the warnings issued by the U.S. Food and Drug Administration (FDA) regarding the use of anti-angiogenic drugs ranibizumab and bevacizumab, manufactured by Genentech. Ranibizumab has been found to be associated with increased risk of stroke in elderly patients, while...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics